Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Observational 3Interventional 3Expanded_access 1

Sponsor

Cancer Type

Head & Neck 4Lymphoid 3Genitourinary 3Gastrointestinal 3Other 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Classical hematology 1CNS 1Breast 1

Conditions

Lymphoma 2571Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia, Lymphocytic, Chronic, B-Cell 1771Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Leukemia 1172Hodgkin Disease 1128Lymphoma, Mantle-Cell 1110Burkitt Lymphoma 887Leukemia, Myeloid, Acute 885Lymphoma, B-Cell, Marginal Zone 788Recurrence 779Multiple Myeloma 744Lymphoma, B-Cell 704Myelodysplastic Syndromes 615Neoplasms 494Lymphoma, T-Cell, Cutaneous 479Waldenstrom Macroglobulinemia 470Lymphoma, Large-Cell, Immunoblastic 456Mycosis Fungoides 383Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 382Lymphoma, Large-Cell, Anaplastic 362Sezary Syndrome 321Lymphoma, T-Cell, Peripheral 321Leukemia, Myelogenous, Chronic, BCR-ABL Positive 307Hematologic Neoplasms 299Myeloproliferative Disorders 288Neoplasms, Plasma Cell 270Blast Crisis 261

Interventions

RC-18 2Methotrexate 2olokizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Arthritis, Rheumatoid × Lymphoid × Clear all
NCT03016013 2024-09-26

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

RemeGen Co., Ltd.

Phase 3 Completed
479 enrolled
Lymphoid

Arthritis, Rheumatoid, Lymphoma, Follicular

NCT03120949 2023-10-12

CREDO 4

R-Pharm

Phase 3 Completed
2,106 enrolled 30 charts
Lymphoid

Arthritis, Rheumatoid, Lymphoma, Follicular

NCT02882087 2019-04-03

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

RemeGen Co., Ltd.

Phase 2 Terminated
60 enrolled
Lymphoid

Arthritis, Rheumatoid, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡